5. Very Low Risk
• Expected Patient survival:
More than 20 years :
• Active Surveillance ( Preferred)
• Radiation Therapy
• Radical Prostatectomy
6. Very Low Risk
• Expected Patient survival:
More than 10-20 years :
Active Surveillance
• Expected Patient survival:
Less than 10 years :
Observation
7. Low Risk
• Expected Patient survival:
More than 10 years :
• Active Surveillance ( Preferred)
• Radiation Therapy
• Radical Prostatectomy
Less than 10 years:
Observation
10. FAVOURABLE INTERMEDIATE
Expected Survival >= 10 Years
• Active Surveillance
• EBRT / BT alone
• RP +/- PLND (If nodal metastasis
>=2 %)
Expected Survival <10 Years
• EBRT / BT Alone
• Observation
11. ACTIVE SURVEILLANCE
• Based on ProtecT trial
• Multiparametric MRI &/ or Prostate Biopsy &/or
Molecular tumour analysis.
• PSA – 6 monthly once
• DRE – Annually
• Repeat Biopsy –Annually
• Repeat MRI – Annually
12. OBSERVATION
• Involves monitoring the course of disease with
the intention to deliver palliative therapy for symptoms or change in
examination or PSA that suggests that symptom is imminent.
• Selection of patients with indolent disease or
comorbidities that would impact the expected survival is crucial
17. Clinical and Pathological Features
(HIGH)
• Has no very high risk features and has atleast one high risk feature:
T3a
Grade group-4 / 5
PSA >20 ng/ml
18. VERY HIGH RISK
• Has at least one of the following
T3b- T4
Primary Gleason pattern 5
2 – 3 high risk features
>4 cores with Grade 4 or 5
21. RADIATION TECHNIQUES
• Highly conformal techniques should be used to treat localized
prostate cancer .
• Photon or Proton EBRT are highly effective.
• Accuracy of the treatment should be verified by daily prostate
localization with any of the following :-
IGRT Using CT
USG
Implanted fiducials
Electromagnetic tracking / targeting .
22. IGRT
• Image-guided RT (IGRT) allows for the adjustment of
patient daily set up as well as the positional correction of
the radiation beams during radiation delivery .
• A consequence of modern, high-conformality RT,
however, is the risk of a “geographic miss”.
• Geometric uncertainty include target delineation error,
patient setup uncertainty and target position variation
(both day-to-day interfraction motion and intrafraction
movement during the course of treatment delivery.
23. • Additionally, the use of IGRT allows for the reduction
of planning margins .
• Imaging methods :-
Non-radiation-based -ultrasound, electromagnetic
tracking, and MRI systems integrated into the treatment
room or treatment machine.
Radiation-based - static as well as real time tracking,
using either kV, MV, or hybrid methods .
24. DEFINITIVE RT
Favorable Intermediate Risk
• Prophylactic lymph node RT , ADT
is not performed routinely unless
there is aggressive tumour
behaviour.
Unfavorable Intermediate
• Prophylactic Pelvic RT can be
given after assesment.
• ADT must be given unless
contraindicated.
• Duration of ADT can be
reduced if EBRT & BT is
administered.
• SBRT + ADT can be
administered.
25. HIGH and VERY HIGH RISK
• Prophylactic nodal radiation –considered.
• ADT is given unless contraindicated.
• Brachytherapy + ADT / SBRT +ADT can be used .
28. ADJUVANT RADIATION THERAPY
• Treatment is individualized based on age/ co-morbidities /clinical and
pathological information , PSA level and PSADT.
• Molecular assay –if adverse features are present .
• Administered within 1 year of RP and after post-op recovery is
complete.
• Patients with positive margins may benefit the most .
37. • ADT acts by reducing the level of androgen hormones, to prevent the
prostate cancer cells from growing
INDICATIONS
• Intermediate unfavorable prostate cancer
• High risk and Very High Risk Prostate Cancer
• Metastatic Prostate Cancer
• In recurrence after RT or Surgery
• Most patients with T3 are, at the present time, treated with NAHT
followed by RT
38. • Prolongs survival in selected patients.
LHRH Agonist alone
Goserelin , Histrelin , Leuprolide or Triptorelin .
LHRH Agonist + First generation Antiandrogen
Nilutamide, Flutamide or Bicalutamide
LHRH Antagonist
Degarelix
39.
40. TIMING OF ADT
• Intermediate Risk:
• NACT : 3 to 6 months + Concurrent +/- Adjuvant : 6
months
• High and Very High Risk :
NACT : 3 to 6 months + Concurrent +/- Adjuvant : 24 to 36
months
• Metastatic : Gold Standard for metastasis at time of
presentation
41. CASTRATION RESISTANT PROSTATE CANCER
Defined by disease progression despite
androgen depletion therapy (ADT) and may
present as :
o Continuous rise in serum prostate-specific antigen (PSA) levels
o Progression of pre-existing disease
o Appearance of new metastases
42. Second Line Hormonal Therapy
ABIRATERONE ACETATE:
• 1000MG DAILY(250 Mg 4 tabs daily)
• Taken with Prednisone 5mg BD
• FDA approved 1st line therapy in asymptomatic CRPC
• 2nd line therapy after failure of docetaxel
ENZALUTAMIDE:
• Inhibits signaling of androgen receptor
• Poor PS
• Given with GNRH Agonists
43. FOLLOW UP SCHEDULE
• First follow-up : 3 months
• Years 0–1 : Every 3 –4 months
• Years 2–5 : Every 6 months
• Years 5+ : Annually